12/29/2021 | 6 pm |Dr. Evelien Bunnik, Microbiology, Immunology and Molecular Genetics, and Dr. Tom Patterson, Infectious Diseases, are quoted in articles published in Egypt, Turkey, Iraq, Saudi Arabia, Yemen, United Arab Emirates, Malaysia, Tunisia, Canada, Singapore and Germany about their study — called Adaptive COVID-19 Treatment Trial (ACTT)-1 or ACTT-2 clinical trials — which found that infection-fighting B cells retain better memory of the coronavirus spike protein in patients who recover from less-severe cases of COVID-19 than in those recovering from severe COVID-19; these findings were published in the journal PLOS ONE

Links are not available.

Article Categories: Stop the Spread